The Number of Positive Tumor Markers (NPTM) Achieves Higher Value in the Prognosis Prediction of Gastric Cancer
Table 2
Correlation between NPTM and major clinic-pathological traits.
Patient characteristics
NPTM
value
0
1
2
3
4
Gender
Female
150 (32.7)
65 (26.6)
30 (25.4)
18 (26.5)
13 (33.3)
0.324
Male
309 (67.3)
179 (73.4)
88 (74.6)
50 (73.5)
26 (66.7)
Age at diagnosis
≤60
262 (57.1)
130 (53.3)
53 (44.9)
27 (39.7)
14 (35.9)
0.004
>60
197 (42.9)
114 (46.7)
65 (55.1)
41 (60.3)
25 (64.1)
Body mass index
<24
260 (56.6)
146 (59.8)
71 (60.2)
43 (63.2)
26 (66.7)
0.622
≥ 24
199 (43.4)
98 (40.2)
47 (39.8)
25 (36.8)
13 (33.3)
Family history
No
397 (86.5)
202 (82.8)
103 (87.3)
62 (91.2)
35 (89.7)
0.363
Yes
62 (13.5)
42 (17.2)
15 (12.7)
6 (8.8)
4 (10.3)
Hypertension
No
375 (81.7)
201 (82.4)
96 (81.4)
47 (69.1)
31 (79.5)
0.154
Yes
84 (18.3)
43 (17.6)
22 (18.6)
21 (30.9)
8 (20.5)
Diabetes
No
425 (92.6)
222 (91.0)
101 (85.6)
64 (94.1)
34 (87.2)
0.125
Yes
34 (7.4)
22 (9.0)
17 (14.4)
4 (5.9)
5 (12.8)
Differentiation grade
Well
81 (17.6)
58 (23.8)
31 (26.3)
20 (29.4)
14 (35.9)
0.014
Moderate
97 (21.1)
42 (17.2)
24 (20.3)
16 (23.5)
2 (5.1)
Poorly
281 (61.2)
144 (59.0)
63 (53.4)
32 (47.1)
23 (59.0)
Tumor location
Upper
75 (16.3)
53 (21.7)
27 (22.9)
18 (26.5)
10 (25.6)
0.395
Middle
118 (25.7)
56 (23.0)
28 (23.7)
17 (25.0)
7 (17.9)
Lower
266 (58.0)
135 (55.3)
63 (53.4)
33 (48.5)
22 (56.4)
Tumor size (cm)
<5
256 (55.8)
115 (47.1)
48 (40.7)
21 (30.9)
12 (30.8)
<0.001
≥ 5
203 (44.2)
129 (52.9)
70 (59.3)
47 (69.1)
27 (69.2)
pTNM
I
74 (16.1)
19 (7.8)
5 (4.2)
1 (1.5)
0 (0.0)
<0.001
II
175 (38.1)
79 (32.4)
33 (28.0)
16 (23.5)
9 (23.1)
III
210 (45.8)
146 (59.8)
80 (67.8)
51 (75.0)
30 (76.9)
Postoperative chemotherapy
No
132 (28.8)
61 (25.0)
37 (31.4)
21 (30.9)
15 (38.5)
0.404
Yes
327 (71.2)
183 (75.0)
81 (68.6)
47 (69.1)
24 (61.5)
Abbreviations: NPTM: number of positive tumor markers; BMI: body mass index; TNM: tumor-node-metastasis staging. Difference between groups was tested by Chi-square test. Statistically significant values are in bold.
